Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2014, Article ID 540236, 7 pages
http://dx.doi.org/10.1155/2014/540236
Research Article

IDH Mutations: Genotype-Phenotype Correlation and Prognostic Impact

1Université Pierre et Marie Curie-Paris 6, Centre de Recherche de l'Institut du Cerveau et de la Moëlle épinière (CRICM) UMR-S975, 75013 Paris, France
2INSERM U 975, 75013 Paris, France
3CNRS, UMR 7225, 75013 Paris, France
4Institut du Cerveau et de la Moëlle épinière (ICM), Plateforme de Génotypage Séquençage, 75013 Paris, France
5AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Laboratoire de Neuropathologie R. Escourolle, 75013 Paris, France
6AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Service de Neurologie 2, 75013 Paris, France
7Fédération de Neurologie Mazarin, Groupe Hospitalier Pitié-Salpêtrière, 75651 Paris Cedex 13, France

Received 14 February 2014; Accepted 7 April 2014; Published 30 April 2014

Academic Editor: Emeline Tabouret

Copyright © 2014 Xiao-Wei Wang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. D. N. Louis, H. Ohgaki, O. D. Wiestler et al., “The 2007 WHO classification of tumours of the central nervous system,” Acta Neuropathologica, vol. 114, pp. 97–109, 2007. View at Google Scholar
  2. D. Figarella-Branger and C. Bouvier, “Histological classification of human gliomas: state of art and controversies,” Bulletin du Cancer, vol. 92, no. 4, pp. 301–309, 2005. View at Google Scholar · View at Scopus
  3. S. W. Coons, P. C. Johnson, B. W. Scheithauer, A. J. Yates, and D. K. Pearl, “Improving diagnostic accuracy and interobserver concordance in the classification and grading of primary gliomas,” Cancer, vol. 79, pp. 1381–1393, 1997. View at Google Scholar
  4. J. M. Kros, “Grading of gliomas: the road from eminence to evidence,” Journal of Neuropathology and Experimental Neurology, vol. 70, no. 2, pp. 101–109, 2011. View at Publisher · View at Google Scholar · View at Scopus
  5. M. J. van den Bent, “Interobserver variation of the histopathological diagnosis in clinical trials on glioma: a clinician's perspective,” Acta Neuropathologica, vol. 120, no. 3, pp. 297–304, 2010. View at Publisher · View at Google Scholar · View at Scopus
  6. D. W. Parsons, S. Jones, X. Zhang et al., “An integrated genomic analysis of human glioblastoma multiforme,” Science, vol. 321, no. 5897, pp. 1807–1812, 2008. View at Publisher · View at Google Scholar · View at Scopus
  7. J. Balss, J. Meyer, W. Mueller, A. Korshunov, C. Hartmann, and A. von Deimling, “Analysis of the IDH1 codon 132 mutation in brain tumors,” Acta Neuropathologica, vol. 116, no. 6, pp. 597–602, 2008. View at Publisher · View at Google Scholar · View at Scopus
  8. F. E. Bleeker, S. Lamba, S. Leenstra et al., “IDH1 mutations at residue p.R132 (IDH1R132) occur frequently in high-grade gliomas but not in other solid tumors,” Human Mutation, vol. 30, no. 1, pp. 7–11, 2009. View at Publisher · View at Google Scholar · View at Scopus
  9. H. Ohgaki and P. Kleihues, “Genetic alterations and signaling pathways in the evolution of gliomas,” Cancer Science, vol. 100, no. 12, pp. 2235–2241, 2009. View at Publisher · View at Google Scholar · View at Scopus
  10. M. Sanson, Y. Marie, S. Paris et al., “Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas,” Journal of Clinical Oncology, vol. 27, no. 25, pp. 4150–4154, 2009. View at Publisher · View at Google Scholar · View at Scopus
  11. H. Yan, D. W. Parsons, G. Jin et al., “IDH1 and IDH2 mutations in gliomas,” The New England Journal of Medicine, vol. 360, no. 8, pp. 765–773, 2009. View at Publisher · View at Google Scholar · View at Scopus
  12. A. Idbaih, Y. Marie, C. Lucchesi et al., “BAC array CGH distinguishes mutually exclusive alterations that define clinicogenetic subtypes of gliomas,” International Journal of Cancer, vol. 122, no. 8, pp. 1778–1786, 2008. View at Publisher · View at Google Scholar · View at Scopus
  13. B. Boisselier, Y. Marie, M. Labussière et al., “COLD PCR HRM: a highly sensitive detection method for IDH1 mutations,” Human Mutation, vol. 31, no. 12, pp. 1360–1365, 2010. View at Publisher · View at Google Scholar · View at Scopus
  14. S. Everhard, G. Kaloshi, E. Crinière et al., “MGMT methylation: a marker of response to temozolomide in low-grade gliomas,” Annals of Neurology, vol. 60, no. 6, pp. 740–743, 2006. View at Publisher · View at Google Scholar · View at Scopus
  15. A. Idbaih, B. Boisselier, M. Sanson et al., “Tumor genomic profiling and TP53 germline mutation analysis of first-degree relative familial gliomas,” Cancer Genetics and Cytogenetics, vol. 176, no. 2, pp. 121–126, 2007. View at Publisher · View at Google Scholar · View at Scopus
  16. M. Labussière, A. Idbaih, X.-W. Wang et al., “All the 1p19q codeleted gliomas are mutated on IDH1 or IDH2,” Neurology, vol. 74, no. 23, pp. 1886–1890, 2010. View at Publisher · View at Google Scholar · View at Scopus
  17. M. Labussiere, M. Sanson, A. Idbaih, and J.-Y. Delattre, “IDH1 gene mutations: a new paradigm in glioma prognosis and therapy?” Oncologist, vol. 15, no. 2, pp. 196–199, 2010. View at Publisher · View at Google Scholar · View at Scopus
  18. T. Watanabe, S. Nobusawa, P. Kleihues, and H. Ohgaki, “IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas,” American Journal of Pathology, vol. 174, no. 4, pp. 1149–1153, 2009. View at Publisher · View at Google Scholar · View at Scopus
  19. C. Hartmann, J. Meyer, J. Balss et al., “Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas,” Acta Neuropathologica, vol. 118, no. 4, pp. 469–474, 2009. View at Publisher · View at Google Scholar · View at Scopus
  20. K. Ichimura, D. M. Pearson, S. Kocialkowski et al., “IDH1 mutations are present in the majority of common adult gliomas but rare in primary glioblastomas,” Neuro-Oncology, vol. 11, no. 4, pp. 341–347, 2009. View at Publisher · View at Google Scholar · View at Scopus
  21. T. Labuda, J. P. Christensen, S. Rasmussen et al., “MEK kinase 1 is a negative regulator of virus-specific CD8+ T cells,” European Journal of Immunology, vol. 36, no. 8, pp. 2076–2084, 2006. View at Publisher · View at Google Scholar · View at Scopus
  22. P. Metellus, B. Coulibaly, C. Colin et al., “Absence of IDH mutation identifies a novel radiologic and molecular subtype of WHO grade II gliomas with dismal prognosis,” Acta Neuropathologica, vol. 120, no. 6, pp. 719–729, 2010. View at Publisher · View at Google Scholar · View at Scopus
  23. S. Nobusawa, T. Watanabe, P. Kleihues, and H. Ohgaki, “IDH1 mutations as molecular signature and predictive factor of secondary glioblastomas,” Clinical Cancer Research, vol. 15, no. 19, pp. 6002–6007, 2009. View at Publisher · View at Google Scholar · View at Scopus
  24. M. Weller, J. Felsberg, C. Hartmann et al., “Molecular predictors of progression-free and overall survival in patients with newly diagnosed glioblastoma: a prospective translational study of the German Glioma Network,” Journal of Clinical Oncology, vol. 27, no. 34, pp. 5743–5750, 2009. View at Publisher · View at Google Scholar · View at Scopus
  25. H. J. Dubbink, W. Taal, R. van Marion et al., “IDH1 mutations in low-grade astrocytomas predict survival but not response to temozolomide,” Neurology, vol. 73, no. 21, pp. 1792–1795, 2009. View at Publisher · View at Google Scholar · View at Scopus
  26. L. A. M. Gravendeel, N. K. Kloosterhof, L. B. C. Bralten et al., “Segregation of non-p.R132H mutations in IDH1 in distinct molecular subtypes of glioma,” Human Mutation, vol. 31, no. 3, pp. E1186–E1199, 2010. View at Publisher · View at Google Scholar · View at Scopus
  27. G. Cairncross, M. Wang, E. Shaw et al., “Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402,” Journal of Clinical Oncology, vol. 31, pp. 337–343, 2013. View at Google Scholar
  28. M. J. van den Bent, A. A. Brandes, M. J. Taphoorn et al., “Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951,” Journal of Clinical Oncology, vol. 31, pp. 344–350, 2013. View at Google Scholar
  29. J. G. Cairncross, M. Wang, R. B. Jenkins et al., “Benefit from procarbazine, lomustine, and vincristine in oligodendroglial tumors is associated with mutation of IDH,” Journal of Clinical Oncology, 2014. View at Publisher · View at Google Scholar